CRBU News and Press, Caribou Biosciences Inc. From 02/01/24

2024-02-01 08:50:44 ET Summary CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names. CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data ...

2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...

-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 -- -- CB-011 CaMMouflage Ph...

2023-12-13 05:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food ...

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 -- ...

2023-12-07 05:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Using gene therapy, companies can change patients’ DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses. As a result, they can r...

2023-11-26 23:42:58 ET Summary In July, Caribou Biosciences reported positive data from the Antler study of its CAR-T therapy, CB-010, and a $25M investment from PFE. Data from the dose expansion portion of the Antler study are expected in H1'24, but given previous conservative gu...

2023-11-22 13:23:21 ET More on Caribou Bioscience Caribou Biosciences: Antlers Up, Bullish Run In Phase 1 Trials AbbVie ends Caribou agreement on CAR-T therapy development Seeking Alpha’s Quant Rating on Caribou Bioscience Historical earnings data for ...

Caribou Biosciences Inc. (CRBU) is expected to report $-0.38 for Q3 2023

2023-11-07 17:23:40 ET More on Caribou Bioscience Caribou Biosciences: Antlers Up, Bullish Run In Phase 1 Trials Caribou Biosciences, Inc. 2023 Q2 - Results - Earnings Call Presentation AbbVie ends Caribou agreement on CAR-T therapy development Seeking Alpha&...